|
|
|
- ほのか にばし
- 7 years ago
- Views:
Transcription
1 THE JAPANESE JOURNAL OF ANTIBIOTICS ( 33 ) 2002 JA * 1 * * 1) * 2)
2 34( 34 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb ( ) (75.3%) Staphylococcus aureus Enterococcus faecalis E. faecalis Enterococcus spp. S. aureus Peptostreptococcus spp. Escherichia coli Klebsiella pneumoniae, Pseudomonas aeruginosa E. coli P. aeruginosa, Enterobacter cloacae, Citrobacter freundii, K. pneumoniae Bacteroides fragilis group E. coli 30 MIC 128 m g/ml 3 (10%) Extended spectrum b -lactamases (ESBLs) Vancomycin (VCM) metallo-b-lactamase P. aerugiosa ) I II. 1) (75.3%) Table (68.1%) (65.2%) (62.2%) (83.1%) (84.8%)
3 THE JAPANESE JOURNAL OF ANTIBIOTICS ( 35 ) Table Fig (67.3%) 50 (15.0%) 19 (5.7%) (Fig. 1) 2) 2002 Table % 35.0% 6 12 (Table 3) Staphylococcus spp. Enterococcus spp.
4 36( 36 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. Table Table Enterococcus spp., Staphylococcus spp. Enterococcus spp. E. faecalis E. faecium Staphylococcus spp. S. aureus (Table 4) Peptostreptococcus spp. (Table 5) 40 E. coli 17 K. pneumoniae 6 P. aeruginosa 5
5 THE JAPANESE JOURNAL OF ANTIBIOTICS ( 37 ) Table Table E. coli 13 P. aeruginosa 8 E. cloacae 6 C. freundii 4 (Table 6) B. fragilis group B. fragils group Peptostreptococcus spp. Enterococcus spp. B. fragilis group (Fig. 2)
6 38( 38 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. Table Fig ) (Fig. 3) B. fragilis group E. coli (Fig. 4)
7 THE JAPANESE JOURNAL OF ANTIBIOTICS ( 39 ) Fig. 3. Fig. 4.
8 40( 40 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. (Fig. 5) B. fragilis group E. faecalis B. fragilis group (Fig. 6) MRSA S. aureus % (Fig. 7) 4) (1) (Fig. 8) 6 B. fragilis group (20.9%) (18.7%), E.coli (13.6%), (13.2%), Enterococcus spp. (10.1%) E. coli (Fig. 9) Enterococcus spp. (18.5%) (10.9%), (10.6%), P. aeruginosa (9.4%), B. fragilis group (9.4%), E. coli (9.1%) P. aeruginosa, B. fragilis group, E. coli (2) (Fig. 10) E. coli Klebsiella spp Enterococcus spp. E. coli Enterococcus spp. (Fig. 11) Klebsiella spp. Enterobacter spp. (3) (Fig. 12) 6 Enterococcus spp. (21.4%) Staphylococcus spp. (19.6%), B. fragilis group (15.3%) P. aeruginosa (7.1%) 5) Tables 7 25 MIC (1) S. aureus Oxacillin (MPIPC) 16 MIC 2 (Table 7) 2 MIC 0.25 mg/ml m g/ml MRSA Ampicillin (ABPC) MIC 16 m g/ml Vancomycin (VCM) Arbekacin (ABK) MIC 2 mg/ml Teicoplanin (TEIC) MIC 4 m g/ml Gentamicin (GM) 9 MIC 1 m g/ml 7 MIC 64 m g/ml
9 THE JAPANESE JOURNAL OF ANTIBIOTICS ( 41 ) Fig. 5. Fig. 6.
10 42( 42 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. Fig. 7. MRSA Fig. 8.
11 THE JAPANESE JOURNAL OF ANTIBIOTICS ( 43 ) Fig. 9. Fig. 10.
12 44( 44 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. Fig. 11. Fig. 12.
13 THE JAPANESE JOURNAL OF ANTIBIOTICS ( 45 ) Table 7. Staphylococcus aureus
14 46( 46 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. Table 8. Staphylococcus epidermidis
15 THE JAPANESE JOURNAL OF ANTIBIOTICS ( 47 ) Table 9. Enterococcus faecalis
16 48( 48 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. Table 10. Enterococcus avium
17 THE JAPANESE JOURNAL OF ANTIBIOTICS ( 49 ) Table 11. Enterococcus faecium
18 50( 50 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. Table 12. Enterococcus spp
19 THE JAPANESE JOURNAL OF ANTIBIOTICS ( 51 ) Table 13. Streptococcus spp
20 52( 52 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. Table 14. Escherichia coli
21 THE JAPANESE JOURNAL OF ANTIBIOTICS ( 53 ) Table 15. Klebsiella pneumoniae
22 54( 54 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. Table 16. Enterobacter cloacae
23 THE JAPANESE JOURNAL OF ANTIBIOTICS ( 55 ) Table 17. Morganella morganii
24 56( 56 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. Table 18. Pseudomonas aeruginosa
25 Table 19. THE JAPANESE JOURNAL OF ANTIBIOTICS ( 57 ) Peptostreptococcus prevotii 9 * 2002
26 58( 58 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. Table 20. Peptostreptococcus spp
27 Table 21. THE JAPANESE JOURNAL OF ANTIBIOTICS ( 59 ) Bacteroides fragilis group
28 60( 60 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. Table 22. Bacteroides spp
29 THE JAPANESE JOURNAL OF ANTIBIOTICS ( 61 ) Table 23. Fusobacterium spp
30 62( 62 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. Table 24. Prevotella spp
31 THE JAPANESE JOURNAL OF ANTIBIOTICS ( 63 ) Table 25. Veillonella spp
32 64( 64 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. Clindamycin (CLDM) MIC 128 m g/ml (2) S. epidermidis S. epidermidis 7 6 MPIPC MIC 4 m g/ml (Table 8) MIC 8 m g/ml Piperacillin (PIPC) 3 ABPC, GM Fosfomycin (FOM) 2 MPIPC, Tazobactam/Piperacillin (TAZ/PIPC), Flomoxef (FMOX), Cefmenoxim (CMX), Imipenem (IPM), Meropenem (MEPM) CLDM 1 Minocycline (MINO) MIC 0.5 m g/ml Cefazolin (CEZ), Cefotiam (CTM), Cefpirome (CPR), Cefozopran (CZOP) MIC 2 m g/ml (4) Streptococcus spp. Streptococcus spp. 35 TEIC MEPM, VCM, IPM (Table 13) (5) E. coli E. coli 30 MEPM IPM (Table 14) MIC CEZ MIC 32 m g/ml 5 (16.7%) MIC 90 MEPM m g/ml, CPR, Cefepim (CFPM), CZOP, IPM m g/ml PIPC CEZ PIPC MIC m g/ml TAZ/PIPC 2 m g/ml (3) Enterococcus spp. E. faecalis 26 TEIC MIC 0.5 m g/ml IPM, ABPC, VCM, PIPC, TAZ/PIPC MIC 4 m g/ml (Table 9) E. avium 4 TEIC MIC 0.5 m g/ml (Table 10) VCM MIC 2 m g/ml E. faecium 12 VCM TEIC MIC 1 m g/ml (Table 11) Enterococcus spp. 3 IPM, VCM, TEIC Ciprofoxacin (CPFX) Levofoxacin (LVFX) (Table 12) (6) K. pneumoniae K. pneumoniae 9 MIC (Table 15) CTM MIC m g/ml, MIC 90 4 m g/ml b - MIC 90 MEPM Carumonam (CRMN) m g/ml CZOP Aztreonam (AZT) 0.25 m g/ml MIC 90 GM 0.5 m g/ml Amikacin (AMK) 8 m g/ml (7) Enterobacter spp. E. cloacae 8 (Table 16) MEPM, IPM, GM, CFPM, LVFX
33 THE JAPANESE JOURNAL OF ANTIBIOTICS ( 65 ) (8) Morganella morganii M. morganii 1 Table 17 (9) P. aeruginosa P. aeruginosa 13 MIC 90 CPFX 1 m g/ml MEPM, GM 2 m g/ml (Table 18) (10) Peptostreptococcus spp. Peptostreptococcus prevotii 9 MEPM, TEIC, IPM (Table 19) Peptostreptococcus spp. 21 Minocycline (MINO) (Table 20) (11) Bacteroides spp. Bacteroides fragilis group 40 MIC 90 MEPM 1 m g/ml IPM 2 m g/ml, TAZ/PIPC, MINO 4 m g/ml (Table 21) Bacteroides spp. 4 IPM MEPM (Table 22) (12) Fusobacterium spp. Fusobacterium spp. 3 MIC 2 m g/ml (Table 23) (13) Prevottela spp. Prevottela spp. 13 IPM, MEPM (Table 24) (14) Veillonella spp. Veillonella spp. 6 CLDM, CMX, MEPM, CEZ, CPFX ABPC (Table 25) IV ) B. fragilis group ), E.coli 11), Klebsiella spp. Enterococcus spp. Enterococcus spp., Pseudomonas spp. 12), MRSA Staphylococcus spp. E. coli 15 17) VCM, ABK TEIC S. aureus ABK, VCM TEIC GM MINO VCM MIC 4 mg/ml S. aureus, S. epidermidis, E. faecalis Enterococcus spp. E. coli 1990 CEZ 100 m g/ml MIC 10%
34 66( 66 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. 11,13 15) MIC 128 m g/ml 3 (10%) CEZ PIPC MIC TAZ/ PIPC ESBLs CEZ CTM CMZ b - P. aeruginosa IPM 50 m g/ml MIC 20% 24,25) IPM MEPM MIC MIC 16 m g/ml 1 B. fragilis group MIC 100 m g/ml 16 19) Bacteroides spp. Prevotella spp. MRSA Pseudomonas spp. Enterococcus spp. IPM CZOP CAZ VCM ABK VCM, ABK, TEIC metallo-b-lactamase ESBLs CEZ E. coli 1) 1 Jpn. J. Antibiotics 39: , ) 2 Jpn. J. Antibiotics 41: , ) 37: , ) (MRSA) 2: , ) 3: , ) 4: 43 49, ) MRSA 5: , ) Jpn. J. Antibiotics 47: , ) Jpn. J. Antibiotics 47: , ) 24: 40 45, ) Escherichia coli Jpn. J. Antibiotics 49: , ) Pseudomonas aeruginosa Jpn. J. Antibiotics 49: , 1996
35 THE JAPANESE JOURNAL OF ANTIBIOTICS ( 67 ) 13) 1994 Jpn. J. Antibiotics 49: , ) 1995 Jpn. J. Antibiotics 50: , ) 1996 Jpn. J. Antibiotics 52: , ) Bacteroides fragilis group 28: 48 54, ) 29: , ) 30: 36 43, ) 30: , ) 1997 Jpn. J. Antibiotics 53: , ) 1998 Jpn. J. Antibiotics 54: , ) 32: , ) 1999 Jpn. J. Antibiotics 55: , ) 2000 Jpn. J. Antibiotics 55: , ) 2001 Jpn. J. Antibiotics 56: , 2003 BACTERIA ISOLATED FROM SURGICAL INFECTIONS AND ITS SUSCEPTIBILITIES TO ANTIMICROBIAL AGENTS SPECIAL REFERENCES TO BACTERIA ISOLATED BETWEEN APRIL 2002 AND MARCH 2003 NAGAO SHINAGAWA Department of Surgery, Nagoya Midori Municipal Hospital TADATOSHI TAKAYAMA and KOUMEI KATO The Third Department of Surgery, Nihon University, School of Medicine KOICHI HIRATA, TADASHI KATSURAMAKI and MITSUHIRO MUKAIYA The First Department of Surgery, Sapporo Medical University, School of Medicine TAKESHI SATO Department of Surgery, Surugadai Hospital, Nihon University, School of Medicine YASUHIDE USHIJIMA and TOMOHIRO USHIDA Department of Surgery, Saitama National Hospital JIRO YURA Digestive Disease Center, Matsunami General Hospital NAOKI AIKAWA and KAZUHIKO SEKINE Department of Emergency and Critical Care Medicine, School of Medicine, Keio University TADAO MANABE and HIROMITSU TAKEYAMA Nagoya City University Graduate School of Medical Sciences, Department of Gastroenterological Surgery
36 68( 68 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. MASAMITSU HASEGAWA Department of Surgery, Nagoya City Koseiin Hospital NORIAKI TANAKA and HIROMI IWAGAKI Division of Gastroenterological Surgery, Okayama University, School of Medicine MASAAKI TANIGUCHI Department of Surgery, Chita Kosei Hospital KEIJI MASHITA Department of Surgery, Bisai Hospital SYU ISHIKAWA Department of Surgery, Takahama Municipal Hospital AKIRA MIZUNO Department of Surgery, Inabe General Hospital HIROAKI KINOSHITA and KEN MORIMOTO Gastroenterological Surgery, Osaka City University, Graduate School of Medicine SADAYOSHI FUCHIMOTO Department of Surgery, Fukuyama National Hospital HIDEYUKI KIMURA Department of Surgery, Okayama Saiseikai Hospital EIJI KONAGA and HITOSHI TAKEUCHI Department of Surgery, Iwakuni National Hospital TAIJIRO SUEDA and YOSHIO TAKESUE Department of Surgery, Graduate School of Biomedical Sciences, Hiroshima University MIKIO FUJIMOTO Department of Surgery, Fujiidera Municipal Hospital TAKASHI YOKOYAMA and EIZO HIYAMA Department of General Medicine, Hiroshima University, School of Medicine HIROSHI TANIMURA Department of Surgery, Wakayama Rosai Hospital SEIYO IKEDA and YOICHI YASUNAMI Department of Surgery 1, Fukuoka University, School of Medicine HIROKI YAMAUE and HIRONOBU OHNISHI The Second Department of Surgery, Wakayama Medical School YUMIKO SUZUKI Section of Studies, Tokyo Clinical Research Center Tendency of isolated bacteria from infections in general surgery during the period from April 2002 to March 2003 were investigated in a multicenter study in Japan, and the following results were obtained. In this series, 334 strains were isolated from 131 (75.3%) of 174 patients with surgical infections. One hundred and seventy-one strains were isolated from primary infections, and 163 strains were isolated from postoperative infections. From primary infections, anaerobic Gram-positive bacteria were predominant, while aerobic Gram-positive bacteria were predominant from postoperative infections. Among aerobic Gram-positive bacteria, although the isolation rate of Staphylococcus aureus was the highest, followed by that of Enterococcus faecalis
37 THE JAPANESE JOURNAL OF ANTIBIOTICS ( 69 ) from primary infections, the isolation rate of E. faecalis was the highest from postoperative infections. Among anaerobic Gram-positive bacteria, the isolation rate of Peptostreptococcus spp. was the highest from both types of infections. Among aerobic Gram-negative bacteria, Escherichia coli was the most predominantly isolated from primary infections, followed by Klebsiella pneumoniae and Pseudomonas aeruginosa in this order, and from postoperative infections, E. coli was the most predominantly isolated, followed by P. aeruginosa, Enterobacter cloacae, and Citobacter freundii. Among anaerobic Gram-negative bacteria, the isolation rate of Bacteroides fragilis group was the highest from both types of infections. The isolation rate of aerobic Gram-negative bacteria from primary infections and that of aerobic Gram-positive bacteria from postoperative infections were high in the last several years. We noticed no vancomycin-resistant Gram-positive cocci nor P. aeruginosa producing metallob-lactamase. But we noticed cefazolin-resistant E. coli probably producing extended spectrum b -lactamase.
Aug THE JAPANESE JOURNAL OF ANTIBIOTICS (9) 2007 NTT JA
Aug. 2009 THE JAPANESE JOURNAL OF ANTIBIOTICS 62 44 277 (9) 2007 NTT JA 278 (10) THE JAPANESE JOURNAL OF ANTIBIOTICS 62 _ 4 Aug. 2009 2009 4 10 1982 7 2007 2007 4 2008 3 1 229 181 (79.0%) 683 24 395 288
日本化学療法学会雑誌第61巻第6号
β Moraxella catarrhalis Escherichia coli Citrobacter Klebsiella pneumoniae Enterobacter cloacae Serratia marcescens Proteus Pseudomonas aeruginosa Acinetobacter Bacteroides fragilis β Haemophilus influenzae
Staphylococcus epidermidis Streptococcus pneumoniae Staphylococcus epidermidis Streptococcus pneumontae S. epidermidis Table 1. Summary of the organis
Staphylococcus aureus S. aureus (MRSA) vancomycin (VCM), arbekacin (ABK) Streptococcus pneumoniae cefuzonam (CZON), cefpirome (CPR) S. pneumoniae Enterococcus faecalis ampicillin (ABPC), imipenem (IPM)
R06_01
Staphylococcus aureus (MSSA) PCG (N=118,334) 57,369 (48.5%) 判定不能 :3 (0.0%) 60,962 (51.5%) CEZ (N=143,723) I:42 (0.0%) 143,635 (99.9%) R:46 (0.0%) CVA/AMPC (N=19,281) R:14 (0.1%) 19,265 (99.9%) 判定不能 :2
CHEMOTHERAPY
CHEMOTHERAPY VOL.41 S-2 Laboratory and clinical evaluation of teicoplanin CHEMOTHERAPY AUG. 1993 VOL.41 S-2 Laboratory and clinical evaluation of teicoplanin Table 1. Comparative in vitro activity of teicoplanin
04-c-„FŒ{›xŒ¾-4.01
544( 56 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 6 Dec. 25 2003 2. * * Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS 58 6 545( 57 ) 9 5 2003 8 2004 714 565 719 50 20 39 0 9 70 79 44.4 91.7% Escherichia coli
epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia
epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia Table 3. Overall clinical efficacy of cefozopran in
70( 70 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. Meropenem 2002 * * * * * * * * * * * * * * * * * * * * * * NTT Feb. THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 71( 71 ) * * * * 2003 12 22 Meropenem
Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Ent
Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Enterococcus faecalis Klebsiella pneumoniae, Morganella
Feb. THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 11( 11 ) 2003 12 17 (MRSA) penicillin-resistant Streptococcus pneumoniae (PRSP) 3 I. 12( 12 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. 3 1997 1) (1985)
2 2 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 1 Feb Neisseria gonorrhoeae ceftriaxone CTRX % 2010 CTRX 20 FQ staphylococci, E. faecium, N.
Feb. 2016 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 1 1 1 2013 69 11,762 2015 11 16 1994 2013 69 19 11,762 FQ 33 Streptococcus pyogenes, Streptococcus pneumoniae, Moraxella catarrhalis, Haemophilus influenzae
R01
1. 集計対象医療機関数 (1,792 医療機関 ) 13.2% (7 医療機関 ) 900 床以上 N=53 86.8% (46 医療機関 ) 19.2% (70 医療機関 ) 500 899 床 N=365 80.8% (295 医療機関 ) JANIS 参加 * 200 499 床 N=2,231 43.4% (968 医療機関 ) 56.6% (1,263 医療機関 ) JANIS 参加 200
VOL. 43 NO. 4
VOL. 43 NO. 4 Fig. 1. Frequency of Enterococcus species from complicated UTI, 1988-1992. the number * of Enterococcus species/the number of cases with complicated UTI. Fig. 3 Epidemiologic characteristics
CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study
CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study VOL. 41 S 1 Table 2. Levels (Đg/ml or Đg/g) of S-1006 in serum, bile, and tissue (gallbladder) after oral administration
CHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Kle
VOL. 29 NO.8 CHEMOTHERAPY 865 CHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Klebsiella pneumoniae GN-69
ｽﾗｲﾄﾞ ﾀｲﾄﾙなし
第 4 回ひびき臨床微生物シンポジュウム June 24,27, 港ハウス 感受性検査を読む ( 同定検査結果確認やスクリーニング検査と捉えて ) ( 株 ) キューリン小林とも子 キューリン微生物検査課 塗抹鏡検グラム染色 分離培養検査血液 BTB, エッグーヨーク 報告書作成結果承認 同定検査 VITEK TSI,LIM クリスタル NF 薬剤感受性検査 MIC2 ディスク法 薬剤感受性結果 (
1.Streptococcus pneumoniae, Streptococcus pyogenes JC-1,S.aureus Smith,methicillin (DMPPC)- susceptible S. aureus subsp. aureus (MSSA) TR101, DMPPC-resistant S. aureus subsp. aureus (MRSA) TR102, Staphylococcus
Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone
Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone (inoculum size= 106 CFU/ml) (Ĉ-lactamase producer : 2 strains) Fig. 1. Sensitivity distribution of
CHEMOTHERAPY JUN Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter cloacae 27, Proteus rettgeri 7, Proteus inconstans 20, Proteus
VOL. 32 S-4 CHEMOTHERAPY Fig. 1 Chemical structure of sodium cefoperazone Fig. 2 Chemical structure of sodium cefoperazone CHEMOTHERAPY JUN. 1984 Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter
Staphylococcus sp. K.pneumoniae P.mirabilis C.freundii E. cloacae Serratia sp. P. aeruginosa ml, Enterococcus avium >100ƒÊg/ml
CHEMOTHERAPY SEPT. 1992 cefoperazone ceftazidime (CAZ), imipenem (IPM) Staphylococcus sp., Enterococcus (CPZ), faecalis, Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Enterobacter cloacae,
Key words : R-plasmid, Urinary tract infection, E. coli Fig. 1. MIC distribution against E. coli isolated from urinary tract (366 strains) and isolation - frequencies of drug-resistant strains Table 1.
366 12 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 1 8 DNA 2,3 16 12 20 171 2008 12 2010 11 2 3,558 4.44% 1.65% 1.17% 90% 9 Escherichia coli -
Dec. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 365 11 sita oxacin 1 1 1 1 1 1 2 2 3 3 1 1 1 2 3 2012 9 14 sita oxacin STFX 50 mg 10% 2008 1 2008 12 2010 11 2 STFX 1,452 91.4% 1,235/1,351 95.9% 466/486
公開情報 2016 年 1 月 ~12 月年報 ( 全集計対象医療機関 ) 院内感染対策サーベイランス検査部門 Citrobacter koseri Proteus mirabilis Proteus vulgaris Serratia marcescens Pseudomonas aerugino
公開情報 2016 年 1 月 ~12 月年報 ( 全集計対象医療機関 ) 院内感染対策サーベイランス検査部門 検査部門におけるサーベイランスの概要と目的 本サーベイランスの目的は 細菌検査により検出される主要な細菌の分離頻度とその抗菌薬感受性を継続的に収集 解析し 医療機関における主要な細菌ならびに薬剤耐性菌の分離状況を明らかにすることである サーベイランスの対象となる主要菌ならびに薬剤耐性菌の分離率は
Table 1.Resistance criteria Fig.1.The resistance rates of piperacillin,ceftazidime, cefsulodin,imipenem,aztreonam,gentamicin,tobramycin,amikacin,isepamicin,fosfomycin and ofloxacin against 2,793 strains
Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile
Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile Key words: temafloxacin, TA-167, Bacteroides fragilis,
DIC vegetation 1 nonbacterial thrombogenic e
2001 2002 Guidelines for the Prevention and Treatment of Infective Endocarditis (JCS 2003) h 1 1 2 3 4 5 6 7 8 9 2 1 2 3 1 2 3 4 1 2 5 1 2 1 G Streptococcus viridans Streptococcus bovis 2 G Streptococcus
(ABPC), Carbenicillin (CBPC), Surbenicillin (SBPC), Piperacillin (PIPC), Cephalexin (CEX), Cefaclor (CCL), Cephalothin (CET), Cefazolin (CEZ), Cefotia
Key words: Blood culture, Trend of bacterial isolation, Increasing of staphylococcus, Use of new cephems (ABPC), Carbenicillin (CBPC), Surbenicillin (SBPC), Piperacillin (PIPC), Cephalexin (CEX), Cefaclor
CHEMOTHERAPY FEB Table 1. Activity of cefpirome and others against clinical isolates
VOL.39 S-1 CHEMOTHERAPY FEB. 1981 Table 1. Activity of cefpirome and others against clinical isolates VOL.39 S-1 CHEMOTHERAPY FEB. 1991 72 M, 55.5 kg 66 F, 53 kg Chronic bronchitis Bronchopneumonia Peak
Table 1 Antibacterial spectra of CPM and other antimicrobials against anaerobes Fig. 1 In vitro activity of CPM and other antibiotics against B. fragilis (136 strains) Fig. 2 In vitro activity of CPM and
Fig. 1 Chemical structure of DL-8280
Fig. 1 Chemical structure of DL-8280 Fig. 2 Susceptibility of cl in ical isolates to DL4280 Fig. 5 Susceptibility of clinical isolates to DL-8280 Fig. 3 Susceptibility of clinical isolates to DL-8280 Fig.
CHEMOTHERAPY DEC Table 1 Antibacterial spectra of T-1982, CTT, CMZ, CTX, CPZ and CEZ 106 CFU/ml Note: P; Peptococcus, S; Streptococcus, G; Gaffk
VOL. 30 S-3 CHEMOTHERAPY imeumoniae, Serratia marcescens, Proteus sp, CHEMOTHERAPY DEC. 1982 Table 1 Antibacterial spectra of T-1982, CTT, CMZ, CTX, CPZ and CEZ 106 CFU/ml Note: P; Peptococcus, S; Streptococcus,
Table 1.Quality control of MICs for reference strains Table 2.Antimicrobial activity of gatifloxacin against aerobic bacteria Table 4.Antimicrobial activity of gatifloxacin and other quinolones against
CHEMOTHERAPY
CHEMOTHERAPY CHEMOTHERAPY Table 1 Antibacterial activity of Sulbactam/CPZ against standard strains MIC mg/ml Inoculum size 106 CFU/ml * Sulbactam/CPZ= 1: 1 ** Concentration of Sulbactam+ CPZ CHEMOTHERAPY
CHEMOTHERAPY
CHEMOTHERAPY CHEMOTHERAPY Table 1 Antibacterial activity of BRL 28500 against standard strains of bacteria Fig, 1 Sensitivity distribution of ABPC-resistant E. coli isolated from urinary tract Fig. 2 Sensitivity
CHEMOTHERAPY JUNE 1987 Table1 Media used *BHIB, brain heart infusion broth (Difco); /3 -NAD, S -nicotinamidoadeninedinucleotide (Sigma Chemical Co.);
VOL.35 S-2 CHEMOTHERAPY Fig.1 Chemical structure of carumonam CHEMOTHERAPY JUNE 1987 Table1 Media used *BHIB, brain heart infusion broth (Difco); /3 -NAD, S -nicotinamidoadeninedinucleotide (Sigma Chemical
VOL.30 NO.10 CHEMOTHERAPY 1123 Fig,1 Group B case 6 hepatolithiasis,e.k.66 y.0.,f.45kg Postoperative wound infection Fig.2 Group B case 15 gastric cancer,k.k.60 y.o.,m. Postoperative peritonitis Fig.3
VOL.42 S-1
CHEMOTHERAPY APR. 1994 VOL.42 S-1 CHEMOTHERAPY APR. 1994 Table 1. Criteria for evaluation of clinical efficacy by the Japanese Society of Oral and Maxillo-Facial Surgeons Grades of symptoms and numerical
Table 1. Antibacterial activity of cefdinir, cefixime, cefteram, cefuroxime, cefaclor and amoxicillin against standard strains Inoculum size: 108 cells/ml CFDN: cefdinir, CFIX: cefixime, CFTM: cefteram,
Table 1. Concentration of ritipenem in plasma, gallbladder tissue and bile after ritipenem acoxil administration (200 mg t.i.d., 3 days) N.D.: not det
Table 1. Concentration of ritipenem in plasma, gallbladder tissue and bile after ritipenem acoxil administration (200 mg t.i.d., 3 days) N.D.: not detected *: time after last administration Table 2. Concentration
2.7 臨床概要
2.7 臨床概要 A/G Al-P ALT AST AT- AUC AZM BIPM BP BUN CEZ CFPN-PI CFU CLcr Cmax CNS COPD CPFX CRP CS CYP CVA DBT DHP-I DIC DRPM DRPM-DC FAS γ-gtp GCP GNB GNF-GNR GPB HAM - Staphylococcus C P450 -I Full Analysis
THE JAPANESE JOURNAL OF ANTIBIOTICS 63 13 243 ( 37 ) 2007 12 2008 5 19 863 methicillin-susceptible Staphylococcus aureus (MSSA) Escherichia coli levof
242 ( 36 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 3 prulifloxacin * ** ** CMC * ** 2010 2 22 Prulifloxacin ulifloxacin (UFX) 3 1 2003 12 2004 5 19 534 2 2005 12 2006 5 19 805 3 THE JAPANESE JOURNAL OF
Table 1 Survival rates of infected mice given antibiotic doses producing peak serum a) S. aurcus Smith Challenge dose :7 ~10 (5% mucin) CFU/mouse. LD50: 1 ~103 (5% mucin) CFU/mouse. Table 2 Survival rates
MIC MIC...
50 mg 10% 2.7.36 2.7.36 2.7.36... 1 1.6... 1 2.6... 3 3.6... 5 3.16... 5 3.26... 12 3.36... 16 4.6... 17 5.6... 19 6.6... 20 2.7.3.3.16-1 MIC... 9 2.7.3.3.16-2 MIC... 10 2.7.3.3.16-3 MIC E. coli... 11
988 CHEMOTHERAPY NOV. 1971
988 CHEMOTHERAPY NOV. 1971 VOL. 19 NO. 8 CHEMOTHERAPY 989 Effect of medium-ph and inoculum size on activity of SB-PC heart infusion agar, mcg/ml Sensitivity distribution of Staphylococci to SB-PC in surgical
Key words: Antibiotics, Intestinal bacterial flora, Germfree mouse
Key words: Antibiotics, Intestinal bacterial flora, Germfree mouse Table 1 Susceptibility to various antibiotics Antibiotics Abbreviations ABPC: GM: CET: CEZ: CMZ: LMOX: CMX: Bacteriae used Ampicillin
Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates
Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates Table 2-1. Summary of patients treated with grepafloxacin for respiratory infection 1) Out: outpatient,
概要 (2004 年分 ) 本サーベイランスは 参加医療機関において血液および髄液から分離された各種細菌の検出状況や薬剤感受性パターンの動向を把握するとともに 新たな耐性菌の早期検出等を目的とする これらのデータを経時的に解析し臨床の現場に還元することによって 抗菌薬の安全で有効な使用方法や院内感染制御における具体的かつ確実な情報を提供する 検体 ( ) 内は施設数 2002 年 2003 年 2004
表紙ＰＤＦ作成用／ＰＤＦ表紙作成用
2008 Vol.50 No.1 Jpn J School Health Jpn J School Health Jpn J School Health Jpn J School Health Hosen Junior High School, Okayama City Notre Dame Seishin University Graduate School Jpn J School Health
Table 1.Concentration of gatifloxacin (Middle-ear) Table 2.Concentration of gatifloxacin (Paranasal sinuses) Table 3.Concentration of gatifloxacin (Tonsil) Table 4.No.of patients studied Table 5.Background
VOL.35 S-2 CHEMOTHERAPY Table 1 Sex and age distribution Table 2 Applications of treatment with carumonam Table 3 Concentration of carumonam in human
CHEMOTHERAPY Fig. 1 Chemical structure of carumonam Disodium(+)-(Z)-CCE1-(2-amino-4-thiazoly1)-2-[[(2S, -(carbamoyloxymethyl)-4-oxo-1-sulfonato-3-azetidinyll -2-oxoethylidene] amino] oxy] acetate 3S)-2
01-a-”Oı€™JŠY-4.02
Apr. THE JAPANESE JOURNAL OF ANTIBIOTICS 58 2 105( 1 ) Fosfomycin b- 2004 11 24 fosfomycin (FOM) FOM b- (cefazolin (CEZ), cefotiam (CTM), cefmetazole (CMZ) piperacillin (PIPC)) b - AmpC b- FOM glucose-6-phosphate
「薬剤耐性菌判定基準」 改定内容
Ver.3.1 Ver.3.2 改訂内容 (2019 年 1 月 ) 改訂対象改訂前改訂後 メチシリン耐性黄色ブドウ球菌 (MRSA) ペニシリン耐性肺炎球菌 (PRSP) 多剤耐性緑膿菌 (MDRP) 多剤耐性アシネトバクター属 (MDRA) 概要 MPIPC が R の Staphylococcus aureus ( または CFX がディスク拡散法で R ) または選択培地で MRSA と確認された菌微量液体希釈法の基準
日本化学療法学会雑誌第58巻第4号
Escherichia coli Enterococcus faecalisstreptococcus agalactiae Klebsiella pneumoniae Staphylococcus epidermidis E. colie. faecalispseudomonas aeruginosa K. pneumoniae S. agalactiae E. coli E. coli μ p
日本化学療法学会雑誌第53巻第S-3号
moxifloxacin in vitro moxifloxacin in vitro 17 9 6 17 11 21 moxifloxacinmflx in vitro cefdinir CFDNclavulanic acidamoxicillincvaampcclarithromycincamclindamycincldm levofloxacinlvfx 1MFLX Clostridium clostridiiformeclostridium
日本化学療法学会雑誌第51巻第4号
000 000 0 000 0 Methicillin resistant Staphylococcus aureusmrsa.methicillin resistant S. epidermidismrse.0 MRSA MRSE arbekacinabkquinupristindalfopristinqprdpr vancomycin MIC0. ml Streptococcus pneumoniae
概要 (2006 年 1 2 3 月分 ) 本サーベイランスは 参加医療機関において血液および髄液から分離された各種細菌の検出状況や薬剤感受性パターンの動 向を把握するとともに 新たな耐性菌の早期検出等を目的とする これらのデータを経時的に解析し臨床の現場に還元することによって 抗菌薬の安全で有効な使用方法や院内感染制御における具体的かつ確実な情報を提供する 検体 2005 年 2006 年 10~12
浜松地区における耐性菌調査の報告
平成 28 年度浜松地区感染対策地域連携を考える会 2017 年 2 月 22 日 浜松地区 耐性菌サーベイランス報告 浜松医科大学医学部附属病院 感染対策室 概要 平成 19 年 4 月に施行された改正医療法により すべての医療機関において管理者の責任の下で院内感染対策のための体制の確保が義務化されました 本サーベイランスは 静岡県浜松地区 ( 浜松市 湖西市 ) における薬剤耐性菌の分離状況や薬剤感受性の状況を調査し
400 46 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 LVFX 100 mg 3 / 7 150 mg 2 / 7 2 2006 2008 9 LVFX PK PD 2009 7 100 mg 1 3 500 mg 1 1 AUC/MIC
Dec. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 399 45 2012 11 5 LVFX 500 mg 1 1 20 Chlamydia trachomatis C. trachomatismycoplasma genitalium M. genitalium LVFX 1 500 mg 1 1 7 22 22 C. trachomatis 17
Table 1-1. Criteria for evaluation Table 2. Criteria for bacteriological efficacy Table 1-2. Criteria for evaluation Table 3. Reasons for exclusion and drop-out from evaluation (clinical efficacy) Table
CHEMOTHERAPY Fig. 1 Chemical structure of CXM-AX
Fig. 1 Chemical structure of CXM-AX NOV. 1986 Fig. 2 Sensitivity distribution of clinical isolates organisms (106 cells/ml) a Smurcus 27 strains d) P.m irabilis 15 strains b Ecol i 27 strains 111.morganii
THE JAPANESE JOURNAL OF ANTIBIOTICS 68 3 June 2015 Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis % 2 S. pneumon
June 2015 THE JAPANESE JOURNAL OF ANTIBIOTICS 68 3 189 49 1 : 14 1 2 2 3 1 2 3 2015 4 3 1 : 14 CVA/AMPC 1 : 14 27 CVA/AMPC 1 : 14 88.5% Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis